By the time ACHN’s purported Sovaldi-based regimen could get to market, GILD’s Sovaldi + GS-5816 combination ought to be launched, providing a satisfactory option for GT3 patients. GT2 patients can take Sovaldi + Ledipasvir instead of Sovaldi + ribavirin; in the hypothetical scenario we’re discussing, the price of the former would be no greater than the latter.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.